http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016526042-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6855 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D309-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D309-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-062 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D309-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 |
| filingDate | 2014-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2016526042-A |
| titleOfInvention | Antibody drug conjugate |
| abstract | Formula [D- (X) b- (AA) w- (L)-] n -Ab [ where D is the following formula (I) (Where A is R 1 , R 2 and R 3 are H, OR a , OCOR a , OCOOR a , alkyl, alkenyl, alkynyl, etc .; R 3 ′ is COR a , COOR a , CONR a R b etc. Each of R 4 to R 10 and R 12 is alkyl, alkenyl or alkynyl; R 11 is H, COR a , COOR a , alkyl, alkenyl or alkynyl, or R 11 and R 12 + The N + C atoms to which they are attached can form a heterocyclic group; each of R 13 and R 14 is H, COR a , COOR a , alkyl, alkenyl or alkynyl; R a and R b are H, alkyl, alkenyl, alkynyl, etc .; each dotted line represents an optional additional bond) or a pharmaceutically acceptable salt, ester, solvate thereof Are tautomers or stereoisomers; X is an extension group; AA is an amino acid unit; L is phosphorus A group; w is 0 to 12; b is 0 or 1; Ab is a moiety containing at least one antigen binding site; and n is a moiety containing at least one antigen binding site. [D- (X) b- (AA) w- (L)-] group ratios, ranging from 1 to 20] are useful in the treatment of cancer. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021505542-A |
| priorityDate | 2013-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 864.